3 New Strong Buy Ratings from Top-Rated Analysts: 11/04/2025
Are you ready for this jelly? Here’s the latest from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Gilead Sciences (GILD) turns scientific wins into serious investor momentum
- Cardinal Health (CAH) enjoys strong sentiment in a trending sector
- Emcor Group (EME) has gained over 90% since we first alerted. Are you watching?
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
The "Set and Collect" Trading Secret Finally Revealed How regular folks are targeting extra cash daily without watching charts all day. Next profit window: Tomorrow 9:35 AM. See how it works.1. Gilead Sciences (NASDAQ: GILD)
Gilead Sciences isn’t resting on its laurels. With powerhouse HIV treatments fueling growth, new cancer drugs earning headlines, and a robust R&D engine firing on all cylinders, this biotech leader is turning scientific wins into serious investor momentum.
Zen Rating: B (Buy) — see full analysis
Recent Price: $119.79 — get current quote
Max 1-year forecast: $150.00
Why we're watching:
- Strong analyst support: Among the top-rated analysts we track, GILD enjoys 18 Strong Buy, 9 Buy, and 6 Hold ratings. See the ratings
- Wells Fargo researcher John Smith recently raised the price target after Gilead's HIV franchise outperformed in Q3 and the company won the 2025 Prix Galien award for Yeztugo® (Lenacapavir), citing "Transformation in blood cancer care and consistent pipeline execution should support further upside."
- Strong price action: Gilead has enjoyed a 7% surge in the past month and 30%+ annual gains
- Industry ranking context: GILD is currently the 7th highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A. (See more winners in the industry here)
- With a Zen Rating of B (Buy), GILD is in good company — B-rated stocks have historically delivered +19.88%/yr.
- The Component Grades shaping that overall rating show specific areas of strength: GILD has above-average rankings for Financials, Safety, and Value. (See all 7 Zen Component Grades here)
2. Cardinal Health (NYSE: CAH)
Cardinal Health is one of the largest distributors of pharmaceuticals and medical products in the U.S., serving 75% of American hospitals. The company is benefiting from resilient healthcare spending, strategic acquisitions, and strong sentiment in the defensive medical distribution sector.
Zen Rating: B (Buy) — see full analysis
Recent Price: $190.77 — get current quote
Max 1-year forecast: $220.00
Why we're watching:
- Analyst support: CAH currently has 14 Strong Buy, 7 Buy, and 4 Hold ratings among the analysts we track. See the ratings
- A flurry of said ratings are brand-new, following the company’s recent earnings report; for example, Kevin Caliendo of UBS (a top 20% analyst) just maintained their street-high $220 price target.
- In addition to having an above-average Zen Rating of B, it’s in a top-rated industry: The Medical Distribution Industry currently earns an A, and CAH is the top pick within it — ranked #1 of 7 stocks. (See the rest of the list here)
- CAH earns strong Component Grades — an A for both Safety and Sentiment, where it ranks in the top 10% of stocks, and an above-average B for Growth — a solid mix for investors looking for security without price action stalling out. (See all 7 Zen Component Grades here)
3. Emcor Group (NYSE: EME)
Emcor is a leading specialty construction firm with expertise in power transmission, voice & data communications, and fiber optics. It also just so happens to be part of our market-beating Zen Investor portfolio — a pick that has gained 92% since we first alerted. The company is riding some serious growth trends — and the stock’s already impressive rally isn’t showing any signs of stopping.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $675.78 — get current quote
Max 1-year forecast: $800.00
Why we're watching:
- Smart money is digging EME, as evidenced by 10 Strong Buy, 5 Buy ratings among the analysts we track. See the ratings
- Analyst commentary emphasizes EMCOR’s 51.5% annual return, robust momentum, and leadership in complex infrastructure.
- A-Rated Industry: The Engineering & Construction Industry is among the top-rated market niches we track; EME is the 8th highest-rated stock out of 45.
- An excellent Zen Rating: With its Strong Buy (A) rating, EME is in a class of stocks that have enjoyed +32.52% returns per year.
- Key areas of strength as revealed by the Component Grades include Growth and Momentum, where EME earns above-average Bs, ranking in the top 25% of stocks, indicating there’s more gas in the tank for this high-potential ticker. (See all 7 Zen Component Grades here)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.